Therapeutic Solutions
International, Inc. Announces the Appointment of Santosh
Kesari, M.D., Ph.D.
to company Scientific Advisory Board
OCEANSIDE, CA -- October 06, 2015 -- InvestorsHub NewsWire
-- Therapeutics Solutions International, Inc., (OTC
Markets:TSOI) announced today that Santosh
Kesari, M.D., Ph.D., FANA, FAAN, has been appointed to our
Scientific Advisory Board.
Dr. Kesari was previously Professor of Neurosciences at UC San
Diego School of Medicine, and Director of Neuro-oncology at Moores
UCSD Cancer Center. His research investigates the biology of
gliomas with the aim of developing new therapeutics for patients
with brain tumors. Dr. Kesari is currently Professor of
Neurosciences and Chair of the Department of Neuro-Oncology and
Neurotherapeutics at the John Wayne Cancer Institute at Providence
St. Johns Health Center in Santa Monica, CA.
"We are very honored today with the appointment of Dr. Kesari to
our Scientific Advisory Board. Dr. Kesari specializes in the
diagnosis and treatment of primary and metastatic brain tumors and
related disorders in cancer patients. Dr. Kesari has a laboratory
interest in targeted molecular therapeutics, biomarker discovery,
cancer stem cell biology, hydrocephalus, neurotoxicity, and
translating these laboratory discoveries into novel, personalized
clinical trials in cancer patients" said Timothy Dixon, President
and CEO of Therapeutic Solutions International.
“I am honored to be appointed to the Scientific Advisory Board
and look forward to working with the board to help advance new
approaches for unmet needs within Neuro-Oncology and
Neurotherapeutics” commented Dr. Kesari.
As was previously announced on July 9, 2015, Therapeutic
Solutions filed on July 8, 2015, with the United States Patent and
Trademark Office (the USPTO) the accepted U.S. Application No.
62/190170 titled Augmentation of Oncology Immunotherapies by
Pterostilbene Containing Compositions to which Dr. Kesari was a
co-inventor on this Patent filing.
Dr. Kesari received a B.A., Biology and Mathematics 1992 from
University of Pennsylvania, College of Arts and Sciences,
University of Pennsylvania, School of Medicine and in 1996 he
received a Ph.D. in Molecular Biology at the University of
Pennsylvania, School of Medicine, and his M.D. in 1999 from the
University of Pennsylvania, School of Medicine.
About Therapeutic Solutions International,
Inc.
The Company's corporate website is www.therapeuticsolutionsint.com.
Our new products can be viewed on www.projuvenol.com and products
can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United
States Food and Drug Administration. These products are not
intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.
CONTACT INFORMATION